Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone Liposome in Modified BEAM for T-Cell Lymphoma ASCT
NCT05814718Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Apr 2023
- Primary completion
- Dec 2025
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Randomised trial of mitoxantrone-liposome in T-cell lymphoma (2 arms), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: relapse rate of T cell lymphoma at 3 years. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
mitoxantrone-liposome
03
Conditions
T-cell lymphoma
Beyond the preview
Go deeper on NCT05814718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05814718.